Effect of Autologous Cord Blood Mononuclear Cells for Prevention of Bronchopulmonary Dysplasia or Death in Extremely Preterm Neonates
Launched by GUANGDONG WOMEN AND CHILDREN HOSPITAL · Jun 18, 2020
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether infusing a type of blood cells from a baby’s umbilical cord can help prevent a serious lung condition called bronchopulmonary dysplasia (BPD) or death in extremely preterm infants born before 28 weeks of pregnancy. The trial involves 140 babies who will be randomly divided into two groups: one group will receive the cord blood cell infusion, and the other will receive a placebo (a harmless salt solution). The researchers will closely monitor the babies to see if the infusion helps them survive without developing BPD by 36 weeks of age or when they go home.
To participate in this trial, babies must meet certain criteria. They need to be born at the participating hospital, be single births, and be less than 28 weeks gestational age. Parents will need to give their permission for their baby to join the study, and there must be umbilical cord blood available for the procedure. Babies with severe birth defects or certain infections in the mother will not be included in the trial. Families can expect thorough follow-up care, and the study will also look at other health outcomes for the babies over the next two years. This research aims to provide important information that could improve care for preterm infants in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants fulfilling all the following inclusion criteria will be enrolled in this trial: 1. born at study hospital; 2. singleton birth; 3. less than 28 weeks GA 4.Signed informed consent obtained; 5. had available umbilical cord blood (UCB).
- Exclusion Criteria:
- • Those infants are excluded if they were 1. with severe congenital abnormalities; 2.with maternal clinical chorioamnionitis 3. the mother was positive for hepatitis B (HBsAg and/or HBeAg) or C virus (anti-HCV), syphilis, HIV (anti-HIV-1 and -2) or IgM against cytomegalovirus, rubella, toxoplasma and herpes simplex virus.
About Guangdong Women And Children Hospital
Guangdong Women and Children Hospital is a leading medical institution dedicated to advancing healthcare for women and children in China. Renowned for its comprehensive clinical services, research initiatives, and commitment to patient-centered care, the hospital plays a pivotal role in the development and implementation of innovative clinical trials. With a focus on improving health outcomes and addressing critical medical needs, the hospital collaborates with various stakeholders to conduct rigorous research that contributes to the evidence base in women's and children's health. Its multidisciplinary team of healthcare professionals and researchers is dedicated to fostering advancements in medical science and enhancing the quality of care provided to its diverse patient population.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Dongguan, Guangdong, China
Patients applied
Trial Officials
Jie Yang
Study Chair
Guangdong Women and Children Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials